** Immunovant IMVT.O said on Wednesday its experimental treatment, batoclimab, for a type of chronic muscle weakness improved patients' symptoms and that it aimed to use the data to accelerate the development of a newer drug
** Analysts are looking into the development of IMVT-1402, the company's lead therapy candidate and its additional indications for autoimmune disorders
BEST-IN-CLASS AUTOIMMUNE THERAPY EMERGING
** Leerink Partners ("outperform", PT: $52) says the next-gen IMVT-1402 has a competitive advantage due to its convenient, low-volume dosage and is optimistic about the additional data due in 2026
** J.P.Morgan says IMVT-1402 will "outshine others" in indications such as Graves' disease and rheumatoid arthritis
** Oppenheimer Securities ("outperform", PT: $54) believes company's drug, IMVT-1402, has the potential to become the "preferred therapy for several autoimmune disorders"
** Truist Securities views Argenx's ARGX.BR Vyvgart's "first mover advantage coupled with physician comfort" will continue to make it the preferred agent ahead of IMVT-1402 and other competitors
(Reporting by Padmanabhan Ananthan)
((padmanabhan.ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。